Free Trial

Ocugen (OCGN) Competitors

Ocugen logo
$0.93 +0.02 (+2.09%)
As of 02:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OCGN vs. CVAC, PHVS, CRMD, NAGE, BCAX, ELVN, ZYME, LENZ, CMRX, and CDMO

Should you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include CureVac (CVAC), Pharvaris (PHVS), CorMedix (CRMD), Niagen Bioscience (NAGE), Bicara Therapeutics (BCAX), Enliven Therapeutics (ELVN), Zymeworks (ZYME), LENZ Therapeutics (LENZ), Chimerix (CMRX), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical products" industry.

Ocugen vs.

CureVac (NASDAQ:CVAC) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, community ranking, risk and media sentiment.

CureVac has a net margin of 20.72% compared to Ocugen's net margin of -532.51%. CureVac's return on equity of 21.98% beat Ocugen's return on equity.

Company Net Margins Return on Equity Return on Assets
CureVac20.72% 21.98% 15.72%
Ocugen -532.51%-154.75%-90.79%

17.3% of CureVac shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Comparatively, 4.4% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ocugen has lower revenue, but higher earnings than CureVac. Ocugen is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVac$535.18M1.74-$281.58M$0.825.07
Ocugen$4.52M59.02-$63.08M-$0.19-4.81

Ocugen received 88 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 71.43% of users gave Ocugen an outperform vote while only 56.25% of users gave CureVac an outperform vote.

CompanyUnderperformOutperform
CureVacOutperform Votes
27
56.25%
Underperform Votes
21
43.75%
OcugenOutperform Votes
115
71.43%
Underperform Votes
46
28.57%

CureVac has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 4.21, indicating that its stock price is 321% more volatile than the S&P 500.

In the previous week, CureVac had 1 more articles in the media than Ocugen. MarketBeat recorded 4 mentions for CureVac and 3 mentions for Ocugen. Ocugen's average media sentiment score of 1.26 beat CureVac's score of 0.10 indicating that Ocugen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CureVac
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ocugen
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CureVac currently has a consensus price target of $14.00, indicating a potential upside of 236.54%. Ocugen has a consensus price target of $6.00, indicating a potential upside of 556.53%. Given Ocugen's higher possible upside, analysts plainly believe Ocugen is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CureVac
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ocugen
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Ocugen beats CureVac on 9 of the 17 factors compared between the two stocks.

Get Ocugen News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCGN vs. The Competition

MetricOcugenBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$266.89M$2.93B$5.33B$8.39B
Dividend YieldN/A1.64%5.21%4.11%
P/E Ratio-5.0831.1826.7119.71
Price / Sales59.02398.78386.47120.65
Price / CashN/A168.6838.2534.62
Price / Book5.713.236.774.50
Net Income-$63.08M-$72.35M$3.23B$248.22M
7 Day Performance20.50%2.49%0.48%-0.78%
1 Month Performance26.75%2.45%9.10%11.53%
1 Year Performance-48.66%-24.98%18.56%8.99%

Ocugen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCGN
Ocugen
1.1897 of 5 stars
$0.93
+2.1%
$6.00
+543.1%
-46.9%$272.47M$4.52M-5.1880Positive News
CVAC
CureVac
3.57 of 5 stars
$3.84
+3.2%
$14.00
+264.6%
+6.4%$861.46M$535.18M6.98880News Coverage
Earnings Report
Analyst Revision
Gap Down
PHVS
Pharvaris
1.2631 of 5 stars
$16.44
-0.7%
$40.67
+147.4%
-17.9%$859.65MN/A-5.8730
CRMD
CorMedix
2.0894 of 5 stars
$12.65
+3.0%
$15.00
+18.6%
+135.3%$857.99M$82.55M-15.6230Positive News
NAGE
Niagen Bioscience
N/A$10.88
-0.6%
N/AN/A$857.02M$107.93M64.00120News Coverage
Gap Down
BCAX
Bicara Therapeutics
1.6377 of 5 stars
$15.40
+6.4%
$32.00
+107.8%
N/A$839.85MN/A0.0032News Coverage
Analyst Downgrade
Gap Down
ELVN
Enliven Therapeutics
2.4752 of 5 stars
$16.84
-0.1%
$37.25
+121.2%
-26.7%$826.32MN/A-8.8650Gap Up
ZYME
Zymeworks
3.3572 of 5 stars
$11.79
+0.7%
$21.00
+78.1%
+27.3%$820.31M$93.38M-7.86460News Coverage
Positive News
Analyst Forecast
Analyst Revision
LENZ
LENZ Therapeutics
1.9254 of 5 stars
$28.57
+6.6%
$46.60
+63.1%
+53.3%$804.13MN/A-16.14110
CMRX
Chimerix
0.5651 of 5 stars
$8.54
flat
$8.53
-0.1%
N/A$801.09M$212,000.00-9.0990
CDMO
Avid Bioservices
0.806 of 5 stars
$12.50
+0.1%
$12.25
-2.0%
+37.5%$799.18M$139.91M-5.23320High Trading Volume

Related Companies and Tools


This page (NASDAQ:OCGN) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners